ACRS · Aclaris Therapeutics, Inc. · Proposed Sales
$3.96
+0.17 (+4.49%)
At close · Oct 28
Return incl. dividend (before tax)
Q1 2024 earnings call transcript
Market Cap
$582.91M
Shares
147.20M
Volume · Oct 28
3.88M
Avg daily vol (3M)
2.89M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2023-10-23 | JOSEPH B MONAHAN | Officer | 6,000 | 2023-10-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2023-08-21 | JOSEPH B MONAHAN | Officer | 6,000 | 2023-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2023-06-20 | JOSEPH B MONAHAN | Officer | 6,000 | 2023-06-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Showing 1–3 of 3 filings
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
27 filings
22 filers
Visit website
Investor relations